Efficacy of care manager-led support for family caregivers of people with dementia during the COVID-19 pandemic: a randomized controlled study. Kazawa K, et al, BMC Geriatr 2022.
- Proposé le : 21/12/2024 04:07:13
- Par : Bot
- Avec la version du site : v2021_01_12
- Revu par :
- Mettre votre nom d'utilisateur
- Mettre votre nom d'utilisateur
Résumé et points clés
Methods: Fifty-three family members (aged ≥20 years) who were primary caregivers living with older PWD using public long-term care services were enrolled in an one-month randomized controlled trial. This duration was set based on behavior modification theory and with consideration of ethical issue that the most vulnerable people not benefiting from the intervention. The intervention group (IG) received care manager-led information provision and practical support, and the control group (CG) received usual care. Care burden (primary outcome) was measured using the Zarit Caregiver Burden Interview, and secondary outcomes were analyzed using Patient Health Questionnaire-9 (PHQ9), the Fear of COVID-19 Scale, and salivary α-amylase activity. Data were collected at baseline and after 1 month. Multiple regression analysis was conducted to examine the efficacy of the intervention. The participants evaluated the care managers' support.
Results: The participants were randomly divided into IG (n = 27) and CG (n = 26) groups. After the intervention, compared with the CG, there was a decrease in PHQ-9 (β = -.202, p = 0.044) and α-amylase activity in saliva (β = -.265, p = 0.050) in IG. IG also showed an increased fear of COVID-19 after the intervention (β = .261, p = 0.003). With the care managers' support, 57.2% of the participants felt secure in their daily lives and 53.1% agreed that they were able to practice infection prevention suitable for older PWD.
Conclusions: Our findings suggest that the care manager-led intervention may be useful for families of older PWD to enhance behavioral changes in preventing COVID-19 infection and improve their psychological outcomes in the COVID-19 era.
Trial registration: This study was registered on April 2, 2021 (No. UMIN000043820).
Références de l'article
Discussion
- Cette section peut être éditée par les relecteurs, les rédacteurs, les modérateurs et les administrateurs. Elle regroupe l'ensemble des échanges autours de la référence ci-dessus présentée.
- Référez-vous à cette page pour connaître le rôle des utilisateurs et pour participer à la discussion.
- Il n'y a, pour l'instant, aucune discussion en cours.